Login to Your Account



Earnings Roundup

Vertex Rings its 1st Profit Bell After Incivek's 3Q Surge

By Tom Wall
BioWorld Today Contributing Writer

Monday, October 31, 2011

Vertex Pharmaceuticals Inc. reported its first-ever profitable quarter built on better-than-expected sales of hepatitis C drug Incivek (telaprevir).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription